![keylight 1.2 for trial keylight 1.2 for trial](https://i.ytimg.com/vi/9EicRK2omBk/maxresdefault.jpg)
EBT-101 is the first of a unique class of therapeutics with the potential to alleviate a major burden on patients and their families by eradicating viral infections. “We endeavor to provide a one-time curative treatment option to people living with HIV.
KEYLIGHT 1.2 FOR TRIAL TRIAL
“The initiation of this trial is a landmark accomplishment for Excision and an important step towards our goal of developing a cure for patients with HIV,” said Daniel Dornbusch, Chief Executive Officer of Excision.
![keylight 1.2 for trial keylight 1.2 for trial](https://fcp.co/media/kunena/attachments/847/key.jpg)
The trial is supported by a robust preclinical dataset that includes both positive long-term non-human primate safety data and efficacy data in transgenic mice showing functional cures from HIV with EBT-101 treatment. The FIH study is a multicenter, open-label, single ascending dose study designed to evaluate the safety, tolerability and efficacy of EBT-101. 27, 2022 (GLOBE NEWSWIRE) - Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV). First-in-human trial is now open for enrollment.
![keylight 1.2 for trial keylight 1.2 for trial](https://cdn.cnetcontent.com/syndication/mediaserverredirect/869a0b7a508f9a064805d80026f7ad40/original.jpg)
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV.